Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells - Journal of Experimental & Clinical Cancer Research
Source : https://jeccr.biomedcentral.com/articles/10.1186/s13046-022-02360-y
Background Challenges exist in the clinical treatment of luminal estrogen receptor α (ERα)-positive breast cancers (BCs) both to prevent resistance to endocrine therapy (ET) and to treat ET-resistant metastatic BCs...
Conclusions: CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs.
Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35395071/
Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key cell cycle regulators that are frequently dysregulated in human malignancies. CDK4/6 inhibitors are clinically approved for the treatment of...
Conclusion/Relevance: Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key cell cycle regulators that are frequently dysregulated in human malignancies. CDK4/6 inhibitors are clinically approved for the treatment of hormone receptor-positive, HER2-negative (HR /HER2-) breast cancer, but improved specificity and reduced...
Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study
Source : https://www.annalsofoncology.org/article/S0923-7534(22)00383-0/fulltext
In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high risk, early breast cancer demonstrated a clinically meaningful improvement in invasive...
Conclusion: In patients with high risk EBC, adjuvant abemaciclib ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile.
Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
Source : https://ascopubs.org/doi/10.1200/OP.22.00140
In 2020, Johnston et al1 reported the primary results from monarchE, a phase III, open-label randomized clinical trial, following the second preplanned interim analysis after 19 months of median follow-up.
Relevance: To offer a prompt response to these updated analyses, ASCO published a rapid recommendation update of ASCO's selection of optimal adjuvant chemotherapy and targeted therapy guideline5 to address the use of abemaciclib in the adjuvant setting (Table 1). This companion Q and A article addresses some of the questions that clinicians face...
Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35343197/
Human epidermal growth factor receptor 2 (HER2)-negative subset is the most heterogeneous group of metastatic breast cancers (MBCs) as it includes both hormone receptor (HR)-positive and HR-negative breast cancer (or...
Conclusion/Relevance: TNBC has conventionally been treated ineffectively with systemic chemotherapy. Recently, poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged for HER2-negative breast cancer (BC) patients, including TNBC. Olaparib and talazoparib have recently been approved in germline BRCA-mutated (gBRCAm) HER2-negative MBC....